- Home
- TLSI vs MDWD Comparison
TLSI vs MDWD Comparison
Compare TLSI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MDWD
- Stock Information
- Founded
- TLSI 2010
- MDWD 2000
- Country
- TLSI United States
- MDWD Israel
- Employees
- TLSI N/A
- MDWD N/A
- Industry
- TLSI Medical Specialities
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- TLSI Health Care
- MDWD Health Care
- Exchange
- TLSI Nasdaq
- MDWD Nasdaq
- Market Cap
- TLSI 244.3M
- MDWD 235.7M
- IPO Year
- TLSI N/A
- MDWD 2014
- Fundamental
- Price
- TLSI $6.21
- MDWD $18.20
- Analyst Decision
- TLSI Strong Buy
- MDWD Strong Buy
- Analyst Count
- TLSI 3
- MDWD 2
- Target Price
- TLSI $10.67
- MDWD $37.50
- AVG Volume (30 Days)
- TLSI 114.0K
- MDWD 63.3K
- Earning Date
- TLSI 11-13-2025
- MDWD 11-20-2025
- Dividend Yield
- TLSI N/A
- MDWD N/A
- EPS Growth
- TLSI N/A
- MDWD N/A
- EPS
- TLSI N/A
- MDWD N/A
- Revenue
- TLSI $40,207,000.00
- MDWD $20,932,000.00
- Revenue This Year
- TLSI $57.25
- MDWD $21.39
- Revenue Next Year
- TLSI $54.05
- MDWD $23.01
- P/E Ratio
- TLSI N/A
- MDWD N/A
- Revenue Growth
- TLSI 49.52
- MDWD 6.15
- 52 Week Low
- TLSI $3.42
- MDWD $14.14
- 52 Week High
- TLSI $6.36
- MDWD $22.51
- Technical
- Relative Strength Index (RSI)
- TLSI 77.66
- MDWD 51.25
- Support Level
- TLSI $3.79
- MDWD $16.66
- Resistance Level
- TLSI $4.88
- MDWD $18.62
- Average True Range (ATR)
- TLSI 0.47
- MDWD 0.70
- MACD
- TLSI 0.17
- MDWD -0.04
- Stochastic Oscillator
- TLSI 96.84
- MDWD 66.89
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.